The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a huge mover today! About 355,322 shares traded hands. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has risen 75.61% since March 8, 2016 and is uptrending. It has outperformed by 66.30% the S&P500.
The move comes after 6 months negative chart setup for the $1.95B company. It was reported on Oct, 11 by Barchart.com. We have $17.18 PT which if reached, will make NASDAQ:LXRX worth $136.50 million less.
Analysts await Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to report earnings on November, 4. They expect $-0.50 earnings per share, down 47.06% or $0.16 from last year’s $-0.34 per share. After $-0.37 actual earnings per share reported by Lexicon Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 35.14% negative EPS growth.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Coverage
Out of 5 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Lexicon Pharmaceuticals has been the topic of 8 analyst reports since August 4, 2015 according to StockzIntelligence Inc. As per Friday, August 5, the company rating was maintained by Wedbush. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earned “Buy” rating by Citigroup on Tuesday, August 2. The stock has “Overweight” rating given by JP Morgan on Monday, August 10. As per Monday, September 28, the company rating was upgraded by Gabelli. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earned “Sell” rating by Gabelli on Friday, September 18. H.C. Wainwright initiated the shares of LXRX in a report on Friday, October 7 with “Buy” rating.
According to Zacks Investment Research, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery.”
LXRX Company Profile
Lexicon Pharmaceuticals, Inc. (Lexicon), incorporated on July 7, 1995, is a biopharmaceutical company. The Firm focuses on the development of treatments for human disease. The Firm is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.